Clinical breast cancer最新文献_第4页

Muscle Quality May Improve With Regular Exercise, Improving the Prognosis for Breast Cancer Patients. 定期运动可以改善肌肉质量，改善乳腺癌患者的预后。

IF 2.9 3区医学

Clinical breast cancer Pub Date : 2024-12-05 DOI: 10.1016/j.clbc.2024.12.005

Kadri Altundag

引用次数: 0

A Comparative Analysis of the Value of HER2 Immunohistochemistry Scoring in Primary and Metastatic Breast Cancer, in the Era of HER2 "Low" Breast Cancers. 在HER2“低”乳腺癌时代，HER2免疫组化评分在原发性和转移性乳腺癌中的价值比较分析

IF 2.9 3区医学

Clinical breast cancer Pub Date : 2024-12-04 DOI: 10.1016/j.clbc.2024.11.017

Swati Bhardwaj, Shabnam Jaffer

{"title":"A Comparative Analysis of the Value of HER2 Immunohistochemistry Scoring in Primary and Metastatic Breast Cancer, in the Era of HER2 \"Low\" Breast Cancers.","authors":"Swati Bhardwaj, Shabnam Jaffer","doi":"10.1016/j.clbc.2024.11.017","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.11.017","url":null,"abstract":"Background: In the DESTINY-B04 trial, patients with pretreated HER2 low metastatic breast cancer (defined as immunohistochemistry score of 1+ or 2+ and negative in situ hybridization) had significant survival improvement with Trastuzumab therapy.Methods: The goal of our study was to compare the HER2 immunohistochemistry scores of paired primary and metastatic breast cancer, with emphasis on HER2 low criteria and its implications for detailed immunohistochemistry interpretation. Using the pathology database from 2011, we identified 272 cases of primary breast cancers with paired metastases. We reviewed and performed immunohistochemistry concordance between the primary and metastases and calculated the HER2 low incidence.Results: Compared to the primary, HER2 immunohistochemistry score in the metastases remained the same in 156/272 cases (57%) and by immunohistochemistry was: 0 (67/114 = 59%), 1+ (22/52 = 42%), 2+ (34/67 = 51%), 3+ (33/39 = 85%) and HER2 low (85/119 = 71%). The HER2 score changed from 0 to HER2 low in 46 cases (17%) and vice versa in 30 (11%).Conclusions: The concordance rate of HER2 immunohistochemistry scores was 57%, highest in 3+ cases, followed by HER2 low and then HER2 negative. The incidence of HER2 low was higher in the metastases by 6% compared to the primary. HER2 should be tested in all metastases and compared with the primary, due to differences in scores as seen in 28% of our cases, which may have clinical implications in the new HER2 low era.","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Universal Genetic Counseling and Testing for Black Women: A Risk-Stratified Approach to Addressing Breast Cancer Disparities. 黑人妇女普遍遗传咨询和检测：解决乳腺癌差异的风险分层方法。

IF 2.9 3区医学

Clinical breast cancer Pub Date : 2024-12-04 DOI: 10.1016/j.clbc.2024.11.024

Versha A Pleasant, Sofia D Merajver

引用次数: 0

Investigation of HOTAIR rs12826786, rs920778 and rs4759314 Variants With Breast Cancer Susceptibility and Clinicopathological Characteristics in a Mexican Population. HOTAIR rs12826786、rs920778和rs4759314变异与墨西哥人群乳腺癌易感性和临床病理特征的研究

IF 2.9 3区医学

Clinical breast cancer Pub Date : 2024-12-03 DOI: 10.1016/j.clbc.2024.11.021

Mónica Alejandra Rosales-Reynoso, Clara Ibet Juárez-Vázquez, Isabel Nohemí García-Sánchez, Alejandra Palacios-Ramírez, Miriam Yadira Godínez-Rodríguez, César de Jesús Tovar-Jácome, Claudia Azucena Tapia-Leyva, Gerardo Emmanuel Robledo-López, José Elías García-Ortiz, Efraín Salas-González, Aldo Antonio Alcaraz-Wong, Martha Patricia Gallegos-Arreola

{"title":"Investigation of HOTAIR rs12826786, rs920778 and rs4759314 Variants With Breast Cancer Susceptibility and Clinicopathological Characteristics in a Mexican Population.","authors":"Mónica Alejandra Rosales-Reynoso, Clara Ibet Juárez-Vázquez, Isabel Nohemí García-Sánchez, Alejandra Palacios-Ramírez, Miriam Yadira Godínez-Rodríguez, César de Jesús Tovar-Jácome, Claudia Azucena Tapia-Leyva, Gerardo Emmanuel Robledo-López, José Elías García-Ortiz, Efraín Salas-González, Aldo Antonio Alcaraz-Wong, Martha Patricia Gallegos-Arreola","doi":"10.1016/j.clbc.2024.11.021","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.11.021","url":null,"abstract":"Background: Breast cancer (BC) is a multifactorial disease of unknown etiology whose major risk factors are genetic alterations of cell proliferation and migration pathways. HOX transcript antisense RNA gene (HOTAIR) is a long noncoding RNA (lncRNA) related to cell proliferation, progression, invasion, metastasis, and poor survival of multiple cancers, including BC. Controversial results have emerged on the association between breast cancer risk in multiple ethnicities. This study explores the association of rs12826786, rs920778, and rs4759314 variants in the HOTAIR gene in BC patients.Methods: DNA of peripheral blood samples was obtained from 588 women (289 patients and 299 control females). Genotypes were identified using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) methodology. The association was calculated using the odds ratio (OR) test. p-values were adjusted by the Bonferroni test (0.016).Results: The rs12826786 (C > T), rs920778 (T > C), and rs4759314 (A > G) variants were associated with BC and with TNM stage, histologic type, and histologic molecular subtype (P = .001). Likewise, the haplotype C-T-G in the HOTAIR gene (rs12826786-rs920778-rs4759314) was significantly related to BC (OR = 5.44, 95% CI, 2.22-13.32, P = .001).Conclusion: The results suggest that rs12826786, rs920778, and rs4759314 variants in HOTAIR significantly influence breast cancer risk.","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Breast Cancers With Intermediate Estrogen Receptor Expression: Characteristics, Prognosis and Treatment. 中间雌激素受体表达的乳腺癌：特点、预后和治疗。

IF 2.9 3区医学

Clinical breast cancer Pub Date : 2024-12-03 DOI: 10.1016/j.clbc.2024.11.020

Ioannis A Voutsadakis

{"title":"Breast Cancers With Intermediate Estrogen Receptor Expression: Characteristics, Prognosis and Treatment.","authors":"Ioannis A Voutsadakis","doi":"10.1016/j.clbc.2024.11.020","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.11.020","url":null,"abstract":"In the era of personalized oncology biomarkers that identify subgroups of specific cancers and help predict response to specific therapies are critical tools for prognosis determination and therapeutic decisions. The Estrogen Receptor (ER) had been one of the first biomarkers used in breast cancer and has helped advance the field of breast oncology by contributing to the success of hormonal therapies for the ER positive subgroup of the disease. Expression of the receptor in 1% or more of tumor cells in immunohistochemical sections define currently the ER positive subgroup of breast cancers, which may be treated with regimens that include hormonal inhibitors. The highest sensitivity and benefit of hormonal therapies is observed in cancers with robust ER expression (in 90% to 100% of tumor cells). However, it has become clear that the subgroup of breast cancers with low ER expression (in 1% to 10% of tumor cells) behaves similarly to ER negative breast cancers and has an inferior response to hormonal therapies. The behavior of the rest of ER positive breast cancers with an intermediate ER expression between these 2 extremes (ER expression between 10% and 90%) is less well described and their response to estrogen targeting therapies is less clear. Breast cancers with intermediate ER expression represent a small subgroup of ER positive breast cancers and the wide range of expressions suggests heterogeneity. This review will discuss this subgroup of ER positive breast cancers and examine their genomic landscape and therapeutic repercussions.","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142876329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical and Multiomic Features Differentiate Young Black and White Breast Cancer Cohorts Derived by Machine Learning Approaches. 临床和多组学特征区分由机器学习方法得出的年轻黑人和白人乳腺癌队列。

IF 2.9 3区医学

Clinical breast cancer Pub Date : 2024-11-28 DOI: 10.1016/j.clbc.2024.11.015

Kawther Abdilleh, Boris Aguilar, George Acquaah-Mensah

{"title":"Clinical and Multiomic Features Differentiate Young Black and White Breast Cancer Cohorts Derived by Machine Learning Approaches.","authors":"Kawther Abdilleh, Boris Aguilar, George Acquaah-Mensah","doi":"10.1016/j.clbc.2024.11.015","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.11.015","url":null,"abstract":"Background: There are documented differences in Breast cancer (BrCA) presentations and outcomes between Black and White patients. In addition to molecular factors, socioeconomic, racial, and clinical factors result in disparities in outcomes for women in the United States. Using machine learning and unsupervised biclustering methods within a multiomics framework, here we sought to shed light on the biological and clinical underpinnings of observed differences between Black and White BrCA patients.Materials and methods: We examined The Cancer Genome Atlas BrCA samples from stage II patients aged 50 or younger that are Black (BAA50) or White (W50) (n = 139 patients; 36 BAA50 and 103 W50) These patients were chosen because marked differences in survival were observed in an earlier study. A variety of multiomic data sets were analyzed to further characterize the clinical and molecular disparities for insights.Results: We coupled RNAseq data with protein-protein interaction as well as BrCA-specific protein co-expression network data to identify 2 novel biclusters. These biclusters are significantly associated with clinical features including race, number of lymph nodes involved with disease, estrogen receptor status, progesterone receptor status and menopausal status. There were also differentially mutated genes. Using DNA methylation data, we identified differentially methylated genes. Machine learning algorithms were trained on differential methylation values of driver genes. The trained algorithms were successful in predicting the bicluster assignment of each sample.Conclusion: These results demonstrate that there was a significant association between the cluster membership and BAA50 and W50 cohorts, indicating that these biclusters accurately stratify these cohorts.","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heart Rate Variability and Cytokines are Involved in Anxiety in Breast Cancer Patients: A Cross-Sectional Study. 心率变异性和细胞因子参与乳腺癌患者的焦虑：一项横断面研究。

IF 2.9 3区医学

Clinical breast cancer Pub Date : 2024-11-28 DOI: 10.1016/j.clbc.2024.11.014

Qianqian Zhang, Wen Li, Sheng Yu, Jian Xu, Lingxue Tang, Senbang Yao, Huaidong Cheng

{"title":"Heart Rate Variability and Cytokines are Involved in Anxiety in Breast Cancer Patients: A Cross-Sectional Study.","authors":"Qianqian Zhang, Wen Li, Sheng Yu, Jian Xu, Lingxue Tang, Senbang Yao, Huaidong Cheng","doi":"10.1016/j.clbc.2024.11.014","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.11.014","url":null,"abstract":"Objective: To explore the correlation between heart rate variability (HRV), peripheral cytokines, anxiety and pain scores in patients with breast cancer (BC).Methods: We collected blood samples from 100 BC patients and measured the concentrations of Interleukin 6 (IL-6), Interleukin 4 (IL-4) and Interferon gamma (IFN-γ). We collected the patients' 5-minute dynamic electrocardiograms and evaluated their anxiety and pain levels through the Anxiety Self-Rating Scale and the Short-Form McGill Pain Questionnaire (SF-MPQ) Scale.Results: Compared with patients in the high HRV group, the low HRV group had lower IL-4 levels and higher IFN-γ/IL-4 concentrations. At the same time, the level of anxiety was also higher, but there was no significant difference in pain. Spearman correlation analysis showed that the normal-to-normal cardiac intervals (SDNN), the square root of the mean of the sum of the squares of differences between adjacent normal-to-normal cardiac intervals (RMSSD), high frequency -HRV (HF-HRV) and IL-4 were positively correlated, SDNN and RMSSD were negatively correlated with IFN-γ/IL-4. HRV is negatively correlated with anxiety. Higher SDNN predicts higher IL-4 levels.Conclusion: Our results indicate that BC patients with low HRV are associated with higher levels of inflammation and anxiety. Therefore, the measurement of HRV may serve as an objective and non-invasive measurement method for monitoring the immune system and anxiety problems of BC patients.","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is Progesterone Receptor a Neglected Feature in Breast Cancer? A Retrospective Study Analysing the Clinicopathological Characteristics of Breast Cancer Based on Progesterone Receptor Status. 孕激素受体是乳腺癌中被忽视的特征吗？基于孕激素受体状态分析乳腺癌临床病理特征的回顾性研究。

IF 2.9 3区医学

Clinical breast cancer Pub Date : 2024-11-27 DOI: 10.1016/j.clbc.2024.11.018

Ilda Rodrigues, Rute Fernandes, Ana Ferreira, Deolinda Pereira, Rúben Fernandes, Raquel Soares, Carla Luís

{"title":"Is Progesterone Receptor a Neglected Feature in Breast Cancer? A Retrospective Study Analysing the Clinicopathological Characteristics of Breast Cancer Based on Progesterone Receptor Status.","authors":"Ilda Rodrigues, Rute Fernandes, Ana Ferreira, Deolinda Pereira, Rúben Fernandes, Raquel Soares, Carla Luís","doi":"10.1016/j.clbc.2024.11.018","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.11.018","url":null,"abstract":"Purpose: The aim of this study is to analyse PR independently and its relationship with demographic and clinicopathological information.Introduction: Steroid hormones, particularly estrogen and progesterone, play a crucial role in breast cancer (BC) etiology. Research attention has focused mainly on estrogen while the progesterone impact on breast cancer has yet to be fully uncover. Hormone receptors, including those for estrogen and progesterone, are crucial in BC molecular classification, shaping prognosis and treatment strategies. Beyond its metabolic effects, progesterone and its receptor (PR) have significant clinical implications, impacting clinical outcomes.Materials and methods: The study comprised 2223 women who were diagnosed with BC at the Comprehensive Cancer Centre in Portugal (IPO-Porto) between 2012 and 2016. Variables, including age at diagnosis, body mass index (BMI), laterality, topographic localization, histological type, differentiation grade, tumor stage, estrogen receptor (ER) and Human Epidermal growth factor Receptor 2 (HER2) expression, were stratified according to the expression of Progesterone Receptor. Statistical analysis included Pearson's Chi-squared test, binary and multinomial regression, and Cox proportional hazard model. Statistical significance was set for P < .05.Results: The results reveal a statistical association between PR and BMI, histological type, differentiation grade, tumour stage, ER and HER2. Progesterone receptor negativity is associated with adverse clinical outcomes, including advanced tumor stages, and diminished overall survival.Conclusion: Further research is needed to elucidate the precise contributions of progesterone to breast cancer progression and to optimize therapeutic approaches for improved patient outcomes.","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhancing Early Breast Cancer Diagnosis With Contrast-Enhanced Ultrasound Radiomics: Insights From Intratumoral and Peritumoral Analysis. 增强对比超声放射组学增强早期乳腺癌诊断：来自肿瘤内和肿瘤周围分析的见解。

IF 2.9 3区医学

Clinical breast cancer Pub Date : 2024-11-26 DOI: 10.1016/j.clbc.2024.11.011

Guoqiu Li, Xiaoli Huang, Huaiyu Wu, Hongtian Tian, Zhibin Huang, Mengyun Wang, Qinghua Liu, Jinfeng Xu, Ligang Cui, Fajin Dong

{"title":"Enhancing Early Breast Cancer Diagnosis With Contrast-Enhanced Ultrasound Radiomics: Insights From Intratumoral and Peritumoral Analysis.","authors":"Guoqiu Li, Xiaoli Huang, Huaiyu Wu, Hongtian Tian, Zhibin Huang, Mengyun Wang, Qinghua Liu, Jinfeng Xu, Ligang Cui, Fajin Dong","doi":"10.1016/j.clbc.2024.11.011","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.11.011","url":null,"abstract":"Introduction: To develop and validate contrast-enhanced ultrasound (CEUS) radiomics model for the accurate diagnosis of breast cancer by integrating intratumoral and peritumoral regions.Materials and methods: This study enrolled 333 patients with breast lesions from Shenzhen people's hospital between March 2022 and March 2024. Radiomics features were extracted from both intratumoral and peritumoral (3 mm) regions on CEUS images. Significant features were identified using the Mann-Whitney U test, Spearman's correlation coefficient, and least absolute shrinkage and selection operator logistic regression. These features were used to construct radiomics models. The model's performance was evaluated using the area under the receiver operating characteristic curve, area under curve (AUC), decision curve analysis, and calibration curves.Results: The radiomics models demonstrated robust diagnostic performance in both the training and testing sets. The model that combined intratumoral and peritumoral features showed superior predictive accuracy, with AUCs of 0.872 (95% CI: 0.829, 0.915) and 0.863 (95% CI: 0.770, 0.956), respectively, compared to the intratumoral model alone. Calibration curves indicated excellent agreement between predicted and observed outcomes, with Hosmer-Lemeshow test P = .97 and P= .62 for the both the training and testing sets, respectively. decision curve analysis revealed that the combined model provided significant clinical benefits across a wide range of threshold probabilities, outperforming the intratumoral model in both sets.Conclusion: The radiomics model integrating intratumoral and peritumoral features shows significant potential for the accurate diagnosis of breast cancer, enhancing clinical decision-making and guiding treatment strategies.","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142845944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patterns of Recurrence and Survival Outcomes of HER2-Low Expression in Early-Stage Breast Cancer. 早期乳腺癌中 HER2 低表达的复发模式和生存结果

IF 2.9 3区医学

Clinical breast cancer Pub Date : 2024-11-26 DOI: 10.1016/j.clbc.2024.11.016

Sihua Liu, Beidi Du, Shuling Zhou, Nan Shao, Shaoquan Zheng, Xiaying Kuang, Yunjian Zhang, Yawei Shi, Ying Lin

{"title":"Patterns of Recurrence and Survival Outcomes of HER2-Low Expression in Early-Stage Breast Cancer.","authors":"Sihua Liu, Beidi Du, Shuling Zhou, Nan Shao, Shaoquan Zheng, Xiaying Kuang, Yunjian Zhang, Yawei Shi, Ying Lin","doi":"10.1016/j.clbc.2024.11.016","DOIUrl":"https://doi.org/10.1016/j.clbc.2024.11.016","url":null,"abstract":"Purpose: To characterize site-specific recurrence patterns and survival outcomes of patients with human epidermal growth factor receptor 2 (HER2)-low breast cancer.Methods: This retrospective cohort study included patients diagnosed with early-stage breast cancer at a single institution in China from January 2010 to December 2020. Patterns of the first site of recurrence were compared between patients with HER2-low and HER2-0 tumors using competing risks regression analysis. Disease-free survival (DFS) and overall survival (OS) were evaluated using Kaplan-Meier method.Results: A total of 2055 patients were analyzed (median follow-up 52.3 months), comprising 1102 (53.6%) patients with HER2-low and 953 (46.4%) with HER2-0 tumors. Patients with HER2-0 tumors had a significantly higher 5-year cumulative incidence of visceral recurrence than those with HER2-low tumors (7.20% vs. 4.50%; P = .046), especially for the lung recurrence (4.16% vs. 2.81%; P = .044). In the hormone receptor (HoR)-positive subgroup, HER2-low patients had a significantly higher risk of local recurrence (10-year cumulative incidence rate, 7.58% vs. 2.61%; P = .013) but a relatively lower risk of contralateral breast cancer (10-year cumulative incidence rate, 0.90% vs. 4.53%; P = .044) compared with HER2-0 patients. Nevertheless, there were no significant differences between the HER2-0 and HER2-low patients regarding the time to all sites of recurrence after adjusting other potential risk factors (all P > .05), DFS (P = .763), and OS (P = .106).Conclusion: Site-specific recurrence patterns differ between HER2-low and HER2-0 patients. However, it does not support that HER2-low breast cancer is a distinct prognostic subtype.","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142823534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0